Morgan Stanley on IO Biotech (IOBT): 'We are encouraged by continued meaningful benefits in a second indication (melanoma lead indication)'
Tweet Send to a Friend
Morgan Stanley analyst Michael E Ulz reiterated an Overweight rating and $4.00 price target on IO Biotech (NASDAQ: IOBT).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
